2023
Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review.
Wang L, Grimshaw A, Mezzacappa C, Rahimi Larki N, Yang Y, Justice A. Do Polygenic Risk Scores Add to Clinical Data in Predicting Pancreatic Cancer? A Scoping Review. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 1490-1497. PMID: 37610426, PMCID: PMC10873036, DOI: 10.1158/1055-9965.epi-23-0468.Peer-Reviewed Original ResearchConceptsRoutine risk factorsPancreatic cancerRisk factorsPolygenic risk scoresClinical dataRisk scoreAddition of PRSClinical risk factorsRoutine clinical dataCancer risk predictionDatabase inceptionCancerClinical applicabilityRelevant exposuresGenetic riskRisk predictionCancer-specific polygenic risk scoresScoping ReviewRiskEuropean ancestryPopulation representativeScoresMost studiesAppropriate controlsFactors
2020
Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index
King JT, Yoon JS, Rentsch CT, Tate JP, Park LS, Kidwai-Khan F, Skanderson M, Hauser RG, Jacobson DA, Erdos J, Cho K, Ramoni R, Gagnon DR, Justice AC. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLOS ONE 2020, 15: e0241825. PMID: 33175863, PMCID: PMC7657526, DOI: 10.1371/journal.pone.0241825.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexVeterans Health AdministrationVACO IndexValidation cohortMedical administrative dataDevelopment cohortSARS-CoV-2 testing resultsMortality indexICD-10 diagnosis codesUS Veterans Health AdministrationSARS-CoV-2 infectionPre-existing medical conditionsCOVID-19 mortality riskPeripheral vascular diseaseCOVID-19 patientsCOVID-19 infectionCOVID-19 mortalitySARS-CoV-2Administrative dataLogistic regression modelsRace/ethnicityCohort subgroupsComorbidity indexOverall mortalityComorbid conditions
2019
Increased Fragility Fracture Rates in Older Men With Osteomyelitis
Hsieh E, Shiau S, Nolan O, Gibert CL, Bedimo RJ, Rodriguez-Barradas MC, Justice AC, Womack JA, Yin MT. Increased Fragility Fracture Rates in Older Men With Osteomyelitis. Clinical Infectious Diseases 2019, 69: 1239-1242. PMID: 30715288, PMCID: PMC6743834, DOI: 10.1093/cid/ciz077.Peer-Reviewed Original Research
2016
The musculoskeletal diagnosis cohort
Goulet JL, Kerns RD, Bair M, Becker W, Brennan P, Burgess DJ, Carroll CM, Dobscha S, Driscoll M, Fenton BT, Fraenkel L, Haskell S, Heapy A, Higgins D, Hoff RA, Hwang U, Justice AC, Piette JD, Sinnott P, Wandner L, Womack J, Brandt CA. The musculoskeletal diagnosis cohort. Pain 2016, 157: 1696-1703. PMID: 27023420, PMCID: PMC4949131, DOI: 10.1097/j.pain.0000000000000567.Peer-Reviewed Original ResearchConceptsMSD diagnosisMusculoskeletal disordersMSD cohortIndex dateVeterans Health Administration (VHA) careNumeric rating scale scoreICD-9-CM codesCohort inclusion criteriaNontraumatic joint disordersPain-related treatmentsMore outpatient visitsVeterans Health AdministrationMental health diagnosesRating Scale scoresHigher NRS scoresHealth services researchElectronic health recordsDiagnosis cohortSevere painInpatient visitsNRS scoresOutpatient visitsNeck disordersFirst diagnosisMean ageThe Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Justice AC, Fiellin DA. The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality. Journal Of General Internal Medicine 2016, 31: 492-501. PMID: 26847447, PMCID: PMC4835362, DOI: 10.1007/s11606-015-3571-4.Peer-Reviewed Original ResearchConceptsSubstance use disordersGuideline-concordant careCause mortalityOpioid therapyLong-term opioid therapyUntreated substance use disordersCurrent substance use disorderTerm opioid therapyTime-updated covariatesPrimary care visitsImportant clinical outcomesMulti-modal treatmentUrine drug testingUninfected patientsUntreated patientsCare visitsChronic painClinical outcomesCox regressionDecreased riskHigh comorbidityMortality burdenRehabilitative therapySUD treatmentHigh risk
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients
2009
Hepatitis C treatment completion rates in routine clinical care
Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver International 2009, 30: 240-250. PMID: 19889081, PMCID: PMC3132089, DOI: 10.1111/j.1478-3231.2009.02156.x.Peer-Reviewed Original ResearchConceptsPre-treatment anemiaTreatment completion ratesVA National Patient Care DatabaseHuman immunodeficiency virus (HIV) coinfectionNational Patient Care DatabasePharmacy Benefits Management databaseHepatitis C virus infectionCompletion ratesHigher comorbidity countC virus infectionImmunodeficiency virus coinfectionCoronary artery diseasePatient Care DatabaseRoutine clinical careClinical practice settingTreatment sitesInitiate therapyInterferon useComorbidity countPharmacy recordsStandard interferonArtery diseaseVirus coinfectionMultivariable analysisCare database
2008
Drug Toxicity, HIV Progression, or Comorbidity of Aging: Does Tipranavir Use Increase the Risk of Intracranial Hemorrhage?
Justice AC, Zingmond DS, Gordon KS, Fultz SL, Goulet JL, King JT, Bravata DM, Valdez H, Kraft M, Mattocks KM, Team T. Drug Toxicity, HIV Progression, or Comorbidity of Aging: Does Tipranavir Use Increase the Risk of Intracranial Hemorrhage? Clinical Infectious Diseases 2008, 47: 1226-1230. PMID: 18831696, DOI: 10.1086/592302.Peer-Reviewed Original Research
2004
Disease progression in HIV-infected patients treated with stavudine vs. zidovudine
Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, Team T. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine. Journal Of Clinical Epidemiology 2004, 57: 89-97. PMID: 15019015, DOI: 10.1016/s0895-4356(03)00245-2.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDatabases, FactualDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHIV InfectionsHIV Wasting SyndromeHumansProportional Hazards ModelsProspective StudiesReverse Transcriptase InhibitorsStavudineZidovudineConceptsCells/microLDisease progressionLandmark analysisCox proportional hazards modelEvent-free survivalHIV-1 patientsHIV-1 RNAProportional hazards modelPrevious AIDSStavudine treatmentCD4 countHIV infectionInhibitor useCombination therapyUnadjusted analysesObservational studyHIV-1U.S. cohortHazards modelPatientsZidovudineStavudineNew casesNRTIsProgression